Wealth Enhancement Advisory Services LLC Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 183.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,525 shares of the biopharmaceutical company’s stock after purchasing an additional 9,407 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Alnylam Pharmaceuticals were worth $6,675,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ALNY. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after buying an additional 240,534 shares during the last quarter. Geode Capital Management LLC increased its position in Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after acquiring an additional 75,936 shares during the last quarter. Orbis Allan Gray Ltd increased its position in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares during the last quarter. Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at $662,837,000. Finally, American Century Companies Inc. lifted its holdings in Alnylam Pharmaceuticals by 1.9% in the second quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock valued at $584,957,000 after acquiring an additional 33,411 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total value of $848,055.70. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the completion of the transaction, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 56,955 shares of company stock worth $24,072,733 in the last three months. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $357.98 on Monday. The stock has a market cap of $47.29 billion, a PE ratio of 1,491.58 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The firm has a fifty day moving average price of $409.91 and a 200-day moving average price of $423.98. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ALNY. Needham & Company LLC boosted their price target on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Bank of America cut their target price on shares of Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating for the company in a research report on Monday, January 12th. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price for the company. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Royal Bank Of Canada reduced their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. Twenty-two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $485.21.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.